Knowledge Deficits Related to the QT Interval Could Affect Patient Safety
暂无分享,去创建一个
[1] W. Vieweg. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. , 2002, The Journal of clinical psychiatry.
[2] R. Frothingham,et al. Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin , 2001, Pharmacotherapy.
[3] M Malik,et al. Problems of Heart Rate Correction in Assessment of Drug‐Induced QT Interval Prolongation , 2001, Journal of cardiovascular electrophysiology.
[4] Michael J. Goodman,et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. , 2000, JAMA.
[5] S. Ayis,et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients , 2000, The Lancet.
[6] J. Woodcock,et al. The safety of newly approved medicines: do recent market removals mean there is a problem? , 1999, JAMA.
[7] S. Tang,et al. QT prolongation and Torsades de Pointes associated with clarithromycin. , 1998, The American journal of medicine.
[8] R. Woosley,et al. Pharmacies and prevention of potentially fatal drug interactions. , 1996, JAMA.
[9] J. Vandenbroucke,et al. QT Interval Prolongation Predicts Cardiovascular Mortality in an Apparently Healthy Population , 1991, Circulation.
[10] H. Kennedy,et al. Torsades de pointes associated with drugs and toxins: recognition and management. , 1987, American heart journal.
[11] J. Bigger,et al. The Electrocardiographic and Antiarrhythmic Effects of Imipramine Hydrochloride at Therapeutic Plasma Concentrations , 1979, Circulation.